MIRA Pharmaceuticals, Inc. Common Stock Total Assets
MIRA Pharmaceuticals, Inc. Common Stock total assets. Based on the latest financial reports, MIRA Pharmaceuticals, Inc. Common Stock (MIRA) holds total assets worth $8.20 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see MIRA Pharmaceuticals, Inc. Common Stock stock valuation for the company's overall valuation and market capitalisation.
Total Assets of MIRA Pharmaceuticals, Inc. Common Stock (2020–2025)
Total assets of MIRA Pharmaceuticals, Inc. Common Stock from 2020 to 2025. This chart illustrates how MIRA Pharmaceuticals, Inc. Common Stock's total assets have evolved over time, based on quarterly financial data. See MIRA stock price for real-time trading data and today's change.
MIRA Pharmaceuticals, Inc. Common Stock - Asset Composition Analysis
MIRA Pharmaceuticals, Inc. Common Stock Total Assets Breakdown (December 2025)
MIRA Pharmaceuticals, Inc. Common Stock total assets breakdown as of December 2025. MIRA Pharmaceuticals, Inc. Common Stock's total assets of $8.20 Million consist of 99.7% current assets and 0.3% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 57.2% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2020–2025)
This chart illustrates how MIRA Pharmaceuticals, Inc. Common Stock's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore MIRA Pharmaceuticals, Inc. Common Stock working capital to net assets to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: MIRA Pharmaceuticals, Inc. Common Stock's current assets represent 99.7% of total assets in 2025, an increase from 15.6% in 2020.
- Cash Position: Cash and equivalents constituted 57.2% of total assets in 2025, up from 15.6% in 2020.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2020.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
MIRA Pharmaceuticals, Inc. Common Stock Competitors by Total Assets
Key competitors of MIRA Pharmaceuticals, Inc. Common Stock based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Novartis AG
SW:NOVN
|
Switzerland | CHF118.89 Billion |
|
Virbac SA
PA:VIRP
|
France | €1.82 Billion |
|
AstraZeneca PLC
LSE:AZN
|
UK | GBX116.43 Billion |
|
Zhejiang Int'L Group Co Ltd
SHE:000411
|
China | CN¥17.31 Billion |
|
GuangYuYuan Chinese Herbal Medicine Co Ltd
SHG:600771
|
China | CN¥2.55 Billion |
|
Hubei Guangji Pharmaceutical Co Ltd
SHE:000952
|
China | CN¥2.18 Billion |
|
Firebrick Pharma Ltd
AU:FRE
|
Australia | AU$2.28 Million |
|
Eli Lilly and Company
SA:LILY34
|
Brazil | R$116.58 Billion |
MIRA Pharmaceuticals, Inc. Common Stock - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 200.08 | 2.79 | 4.16 |
| Quick Ratio | 200.08 | 2.79 | 4.16 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $8.13 Million | $534.42K | $1.69 Million |
MIRA Pharmaceuticals, Inc. Common Stock - Advanced Valuation Insights
This section examines the relationship between MIRA Pharmaceuticals, Inc. Common Stock's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.42 |
| Latest Market Cap to Assets Ratio | 2.03 |
| Asset Growth Rate (YoY) | 279.5% |
| Total Assets | $11.09 Million |
| Market Capitalization | $22.57 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values MIRA Pharmaceuticals, Inc. Common Stock's assets at a significant premium (2.03x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: MIRA Pharmaceuticals, Inc. Common Stock's assets grew by 279.5% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for MIRA Pharmaceuticals, Inc. Common Stock (2020–2025)
The table below shows the annual total assets of MIRA Pharmaceuticals, Inc. Common Stock from 2020 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $11.09 Million | +279.52% |
| 2024-12-31 | $2.92 Million | -40.74% |
| 2023-12-31 | $4.93 Million | +474.83% |
| 2022-12-31 | $858.07K | -74.43% |
| 2021-12-31 | $3.36 Million | +14897.83% |
| 2020-12-31 | $22.37K | -- |
About MIRA Pharmaceuticals, Inc. Common Stock
MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a next-generation oral NMDA receptor modulator, that has completed a Phase 1 clinical trial. It also offers oral pharmaceutical mar… Read more